Back to School: Supporting Young Patients in Their Learning Journeys

Back-to-school time can be a challenge. By this point, though, most young learners are already in the classroom. But are they ready to put their best foot forward?

Approximately 7 million (11.7%) US children aged 3 to 17 years have a current attention-deficit/hyperactivity disorder (ADHD) diagnosis, according to data collected from a national survey of parents in 2024.¹ However, only approximately 58% to 80% of children with ADHD are receiving treatment.¹

On July 24, the US Food and Drug Administration (FDA) approved centanafadine (Simtriyo) for the treatment of ADHD in adults and children aged 6 and older. The norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system stimulant is the first FDA-approved NDSRI for ADHD.² This is a novel treatment approach for this condition and could be a boon for children as they focus on learning.

As always, Psychiatric Times was at the ready to provide you with the breaking news. What FDA decision are you anticipating next?

References

1. Data on ADHD in children. CDC. July 8, 2026. Accessed August 3, 2026. https://www.cdc.gov/adhd/data/index.html

2. Otsuka receives FDA approval for first-in-class Simtriyo (centanafadine) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older. News release. Otsuka. July 24, 2026. Accessed July 24, 2026. https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine